Biologic & Biosimilar RA Drugs Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities
Discover trends, market shifts, and competitive outlooks for the biologic & biosimilar ra drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#How Has The Biologic & Biosimilar RA Drugs Market Size Shifted, And What Is the Outlook Through 2034?
Recent years have seen significant growth in the market size of biologic & biosimilar ra drugs. The market is predicted to increase from $13.99 billion in 2024 to $14.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors attributing to its growth during the historic period include market penetration rates, results of clinical trials, variations in market share, long-term results in patients, and pricing strategies.
The market size for biologic and biosimilar ra drugs is set to experience considerable expansion in the coming years, growing to a substantial $19.51 billion by 2029 at a compound annual growth rate (CAGR) of 7.3%. This anticipated growth during the forecast period can be traced to numerous factors such as the escalation in biologic drug development, competitive market landscape, evolving healthcare policies, patient choices, and progress in clinical research and development. Key trends expected during this period include an increase in competition in the biosimilar market, the emergence of personalized medicine and precision therapy, advancements in methods of drug delivery, an emphasis on safety and efficacy, and a patient-focused approach in healthcare.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
What Are the Core Growth Drivers Propelling the Biologic & Biosimilar RA Drugs Market Forward?
The biologics and biosimilar RA drugs market is progressing due to the growing elderly population and the heightened prevalence of rheumatoid arthritis. The term elderly population pertains to individuals who are 60 years of age or more. The immune system of an individual mistakenly attacks its own healthy cells in rheumatoid arthritis, a self-triggered disorder, resulting in joint damage. The disease commonly influences elderly people since the immune system weakens as one gets older. As opposed to traditional medicines, biologics and biosimilar RA drugs are more effective in treating rheumatoid arthritis. For example, the World Health Organization (WHO), a specialized health agency of the United Nations based in Switzerland, reported approximately 1 billion individuals over 60 in 2020 and this is anticipated to rise to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention, a US governmental public health organization, predicts that the number of adults in the USA with arthritis will reach 78.4 million by 2040, with 34.6 million likely to experience arthritis-related activity limitations. Consequently, the escalating elderly populace combined with the growing cases of RA is pushing the biologics and biosimilars RA drugs market ahead.
What Segment Types Define the Biologic & Biosimilar RA Drugs Market Structure?
The biologic & biosimilar RA drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Emerging Trends that Are Influencing theBiologic & Biosimilar RA Drugs Industry Evolution?
The biologic & biosimilar RA drugs market is increasingly being influenced by new innovations, a significant trend gaining traction. A focus for major corporations in this market is the creation of affordable biosimilar treatment alternatives like Dual Concentration Biosimilar Options. An example of this is a collaboration between US-based health company Organon and South Korean biopharmaceutical firm Samsung Bioepis. These companies released a biosimilar of Humira (adalimumab) called HADLIMA in the US market in July 2023. HADLIMA, available in both high and low concentrations, is aimed at increasing affordability and accessibility for patients suffering from autoimmune diseases. Compared to Humira, the biosimilar is offered at an 85% discount, contributing to its wider patient reach. The Arthritis Foundation has recognized the biosimilar, which includes an autoinjector. It is included alongside a patient support program titled HADLIMA For You, which encompasses co-pay support and educational resources. HADLIMA is suggested for a range of medical conditions, including rheumatoid arthritis and Crohn’s disease. As per patient care continuity, it comes in both a high-concentration citrate-free version (100 mg/mL) and a low-concentration citrate-containing version (50 mg/mL).
View the full report here:
What Is the Definition of the Biologic & Biosimilar RA Drugs Market?
Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model